4 Result: 23andMe
Momentum Builds: FDA Clearance Boosts 23andMe; Leidos Scores $7.9B Contract
August 31st, 2023
Shares of 23andMe Holding Co. (Nasdaq: ME) surged over 5% in after-hours trading as the company announced an FDA 510(k) clearance to expand its Genetic Health Risk Report related to BRCA1/BRCA2 variants. This clearance now permits 23andMe to provide . Read more
23andMe: Strategic Move; Oracle, Tesla and Microsoft: PT Boost Hint at Potential Upsides
June 09th, 2023
23andMe Holding Co. (Nasdaq: ME), a leading genetic testing and personal genomics company, has disclosed in a regulatory filing with the SEC a reduction in force involving around 75 employees, representing approximately 9% of its workforce. . Read more
Financial Performance and Clinical Updates: 23andMe, RH, and Aravive - Latest Reports and Future Prospects
May 26th, 2023
In the world of financial markets and healthcare, several companies have recently reported their financial performance and provided updates on their ongoing trials and future prospects. Genetic testing company 23andMe Holding Co. (Nasdaq: ME) disc. Read more
Columbus McKinnon, 23andMe, American Woodmark, and Titan Machinery Set to Announce Financial Results
May 23rd, 2023
Several companies are scheduled to release their financial results on Thursday, May 25, providing insights into their performance during the respective periods. Here are the details of the anticipated reports: Columbus McKinnon Corporation (Nasdaq. Read more
Want To Find Some News?
News By Industries
Recent Post
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login